• Twitter
  • Jobs
ProCURE oncology
  • HOME
  • ABOUT US
  • RESEARCH GROUP
    • Molleví’s Lab
    • Antolin’s Lab
    • Alemany’s & Piulats’s lab
    • Martínez-Balibrea’s Lab
    • Aytes’s Lab
    • Belver’s Lab
    • Pujana’s Lab
    • Menendez’s Lab
    • Sureda’s & Farre’s Lab
    • Casanovas’s Lab
    • Viñals’s lab
  • INNOVATION
  • NEWS
  • CONTACT
  • Menu Menu

Fetal pericallosal lipomas – Clues to diagnosis in the second trimester

15 de August de 2018
Eur J Paediatr Neurol. 2018 Nov;22(6):929-934. doi: 10.1016/j.ejpn.2018.07.011.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2018-08-15 10:00:002018-08-15 10:00:00Fetal pericallosal lipomas – Clues to diagnosis in the second trimester

Orthoxenografts of Testicular Germ Cell Tumors Demonstrate Genomic Changes Associated with Cisplatin Resistance and Identify PDMP as a Resensitizing Agent

6 de April de 2018
Clin Cancer Res. 2018 Aug 1;24(15):3755-3766. doi: 10.1158/1078-0432.CCR-17-1898.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2018-04-06 10:00:002018-04-06 10:00:00Orthoxenografts of Testicular Germ Cell Tumors Demonstrate Genomic Changes Associated with Cisplatin Resistance and Identify PDMP as a Resensitizing Agent

ALK1 Loss Results in Vascular Hyperplasia in Mice and Humans Through PI3K Activation

17 de February de 2018
Arterioscler Thromb Vasc Biol. 2018 May;38(5):1216-1229. doi:…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2018-02-17 11:00:002018-02-17 11:00:00ALK1 Loss Results in Vascular Hyperplasia in Mice and Humans Through PI3K Activation

A Role for CXCR4 in Peritoneal and Hematogenous Ovarian Cancer Dissemination

18 de November de 2017
Mol Cancer Ther. 2018 Feb;17(2):532-543. doi: 10.1158/1535-7163.MCT-17-0643.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2017-11-18 11:00:002017-11-18 11:00:00A Role for CXCR4 in Peritoneal and Hematogenous Ovarian Cancer Dissemination

TGFβ Controls Ovarian Cancer Cell Proliferation

1 de August de 2017
Int J Mol Sci. 2017 Jul 30;18(8):1658. doi: 10.3390/ijms18081658.ABSTRACTThere…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2017-08-01 10:00:002017-08-01 10:00:00TGFβ Controls Ovarian Cancer Cell Proliferation

Two-Dimensional Ultrasound Evaluation of the Fetal Cerebral Aqueduct: Improving the Antenatal Diagnosis and Counseling of Aqueductal Stenosis

24 de April de 2017
Fetal Diagn Ther. 2017;42(4):278-284. doi: 10.1159/000458439.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2017-04-24 10:00:002017-04-24 10:00:00Two-Dimensional Ultrasound Evaluation of the Fetal Cerebral Aqueduct: Improving the Antenatal Diagnosis and Counseling of Aqueductal Stenosis

Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition

20 de December de 2016
Oncogene. 2017 May 11;36(19):2737-2749. doi: 10.1038/onc.2016.427.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2016-12-20 11:00:002016-12-20 11:00:00Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition

Corrigendum: A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect

3 de November de 2016
Nat Commun. 2016 Nov 2;7:13467. doi: 10.1038/ncomms13467.NO ABSTRACTPMID:27804975…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2016-11-03 10:00:002016-11-03 10:00:00Corrigendum: A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect

The pancreatic niche inhibits the effectiveness of sunitinib treatment of pancreatic cancer

5 de July de 2016
Oncotarget. 2016 Jul 26;7(30):48265-48279. doi: 10.18632/oncotarget.10199.ABSTRACTCurrent…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2016-07-05 10:00:002016-07-05 10:00:00The pancreatic niche inhibits the effectiveness of sunitinib treatment of pancreatic cancer

The TGFβ pathway stimulates ovarian cancer cell proliferation by increasing IGF1R levels

15 de June de 2016
Int J Cancer. 2016 Oct 15;139(8):1894-903. doi: 10.1002/ijc.30233.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2016-06-15 10:00:002016-06-15 10:00:00The TGFβ pathway stimulates ovarian cancer cell proliferation by increasing IGF1R levels

Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine Tumors

27 de May de 2016
Clin Cancer Res. 2016 Dec 1;22(23):5805-5817. doi: 10.1158/1078-0432.CCR-15-3051.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2016-05-27 10:00:002016-05-27 10:00:00Therapeutic Benefit of Selective Inhibition of p110α PI3-Kinase in Pancreatic Neuroendocrine Tumors

Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients

3 de May de 2016
Cell Rep. 2016 May 10;15(6):1134-43. doi: 10.1016/j.celrep.2016.04.015.…
https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2016-05-03 10:00:002016-05-03 10:00:00Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients
Page 4 of 10«‹23456›»

Filter by categories

  • Alemany’s & Piulats’s lab (135)
  • Antolin's lab (36)
  • Aytes's Lab (25)
  • Belver's Lab (25)
  • Casanovas's Lab (77)
  • Martínez-Balibrea's Lab (43)
  • Menendez's Lab (121)
  • Molleví's Lab (35)
  • Pujana's Lab (112)
  • Sin categoría (12)
  • Sureda's & Farre's Lab (320)
  • Viñals's lab (114)

Twitter

Tweets by ProcureICO
Program Against Cancer Therapeutic Resistance

CONTACT US

Campus IDIBELL
(L’Hospitalet del Llobregat)
Hospital Duran i Reynals, Gran Via 199,
L’Hospitalet del Llobregat,
Barcelona 08908
Tel. +34 93 260 7952

Campus IGTP-IJC
(Badalona)
Campus Can Ruti – IGTP – Building Muntanya,
Rd. Can Ruti, Camí de les escoles s/n,
Badalona, Barcelona 08916
Tel. +34 93 554 3069

Campus IDIBGI
(Girona)
Parc Hospitalari Martí i Julià de Salt, Dr. Castany s/n,
Salt, Girona 17190
Tel. +34 872 987 087

© Copyright - Edisenius
  • Privacy Policy
  • Cookie Policy
  • Legal Notice
Scroll to top
Manage cookie consent
To offer the best experiences, we use technologies such as cookies to store and/or access device information. Consent to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Failure to consent, or withdrawal of consent, may adversely affect certain features and functions.
Functional Always active
Storage or technical access is strictly necessary for the legitimate purpose of allowing the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. Storage or technical access that is used exclusively for anonymous statistical purposes. Without a requirement, voluntary compliance by your Internet service provider, or additional records from a third party, information stored or retrieved solely for this purpose cannot be used to identify you.
Marketing
Storage or technical access is necessary to create user profiles to send advertising, or to track the user on a website or several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
See preferences
{title} {title} {title}